LY3493269
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 16
Of
16
Go to page
1
January 14, 2025
A Multiple-Dose Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=42 | Terminated | Sponsor: Eli Lilly and Company | Completed ➔ Terminated; Following preplanned review of the safety and pharmacokinetic data from Part A, it was determined that sufficient data had been obtained. The decision was made to not proceed with Part B and the study was terminated early.
Trial termination
August 14, 2023
A Multiple-Dose Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=42 | Completed | Sponsor: Eli Lilly and Company | Recruiting ➔ Completed | N=70 ➔ 42 | Trial completion date: Sep 2023 ➔ Jun 2023 | Trial primary completion date: Sep 2023 ➔ Jun 2023
Enrollment change • Trial completion • Trial completion date • Trial primary completion date
April 18, 2023
A Multiple-Dose Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=70 | Recruiting | Sponsor: Eli Lilly and Company | Not yet recruiting ➔ Recruiting
Enrollment open
April 03, 2023
A Multiple-Dose Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=70 | Not yet recruiting | Sponsor: Eli Lilly and Company
New P1 trial
November 19, 2021
A Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=40; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed
Clinical • Trial completion
October 05, 2021
A Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=56; Active, not recruiting; Sponsor: Eli Lilly and Company; Trial completion date: Aug 2021 ➔ Nov 2021; Trial primary completion date: Aug 2021 ➔ Nov 2021
Clinical • Trial completion date • Trial primary completion date
August 05, 2021
A Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=56; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting
Enrollment closed
June 29, 2021
A Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=56; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
March 22, 2021
A Study of LY3493269 in Participants With Type 2 Diabetes
(clinicaltrials.gov)
- P1; N=56; Completed; Sponsor: Eli Lilly and Company; Active, not recruiting ➔ Completed
Clinical • Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
January 27, 2021
A Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=56; Not yet recruiting; Sponsor: Eli Lilly and Company; Trial completion date: May 2021 ➔ Aug 2021; Initiation date: Feb 2021 ➔ May 2021; Trial primary completion date: Apr 2021 ➔ Aug 2021
Clinical • Trial completion date • Trial initiation date • Trial primary completion date
January 22, 2021
A Safety Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=40; Completed; Sponsor: Eli Lilly and Company; Recruiting ➔ Completed
Clinical • Trial completion
January 20, 2021
A Study of LY3493269 in Participants With Type 2 Diabetes
(clinicaltrials.gov)
- P1; N=56; Active, not recruiting; Sponsor: Eli Lilly and Company; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
December 23, 2020
A Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=56; Not yet recruiting; Sponsor: Eli Lilly and Company
Clinical • New P1 trial
October 07, 2020
A Safety Study of LY3493269 in Healthy Participants
(clinicaltrials.gov)
- P1; N=48; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open
September 04, 2020
A Study of LY3493269 in Participants With Type 2 Diabetes
(clinicaltrials.gov)
- P1; N=56; Recruiting; Sponsor: Eli Lilly and Company; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
August 17, 2020
A Study of LY3493269 in Participants With Type 2 Diabetes
(clinicaltrials.gov)
- P1; N=56; Not yet recruiting; Sponsor: Eli Lilly and Company
Clinical • New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 16
Of
16
Go to page
1